This PRISM update follows the Company’s recent announcement of full-year 2024 revenue growth of 20% to $27.8 million, with gross profit up 64% year-over-year to $2.3 million. Fourth quarter revenue ...
BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback